Related Experiment Video

Updated: Jan 31, 2026

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach
07:49

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach

Published on: July 21, 2023

2.0K

No longer failing to treat heart failure: A guideline update review

Jonathan Parch1, Chloe Powell

  • 1Jonathan Parch practices cardiothoracic surgery at the Smidt Heart Institute at Cedars-Sinai Medical Center in Los Angeles, Calif. Chloe Powell is a clinical instructor of family medicine in the Primary Care Physician Assistant Program at the University of Southern California's Keck School of Medicine in Alhambra, Calif. The authors have disclosed no potential conflicts of interest, financial or otherwise.

JAAPA : Official Journal of the American Academy of Physician Assistants
|December 28, 2018
PubMed

Insights

New heart failure guidelines recommend novel therapies like angiotensin receptor-neprilysin inhibitors and sinoatrial node modulators. These treatments aim to reduce hospitalizations and improve quality of life for heart failure patients.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Heart failure represents a significant global health burden, contributing to high rates of hospitalization and mortality.
  • Current management strategies for Stage C heart failure with reduced ejection fraction are evolving.

Purpose of the Study:

  • To summarize guideline updates concerning advanced pharmacotherapies for heart failure with reduced ejection fraction.
  • To highlight the benefits of novel drug classes in managing heart failure patients.

Main Methods:

  • Review of joint guideline updates from the American Heart Association, American College of Cardiology, and Heart Failure Society of America (2016 and 2017).
  • Analysis of recommendations for angiotensin receptor-neprilysin inhibitors and sinoatrial node modulators.

Main Results:

  • Strong recommendation to substitute angiotensin-converting enzyme inhibitors or angiotensin receptor blockers with angiotensin receptor-neprilysin inhibitors for selected patients.
  • Support for adding sinoatrial node modulators to beta-blocker therapy to further reduce heart rate.

Conclusions:

  • These updated guidelines introduce innovative therapies that can substantially decrease heart failure morbidity and mortality.
  • Implementation of these treatments promises enhanced patient quality of life and reduced healthcare expenditures.

More Related Videos

Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients03:47

Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients

Published on: July 12, 2024

1.2K
Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

7.1K

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
920
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.6K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
882
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
336
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
966
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
312